The feasibility and acceptability of practical, individualised, high intensity aerobic exercise in people with Parkinson's disease.

Not Applicable

Recruiting

• Conditions: Parkinson's disease; Neurological - Parkinson's disease; Physical Medicine / Rehabilitation - Physiotherapy

• Registration Number: ACTRN12623001334695
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Adults aged 40 years and over with mild idiopathic Parkinson's disease (Hoehn & Yahr less than or equal to 2), diagnosed for 5 years or less.
- Stable dopaminergic medication regimen for at least 4 weeks prior to commencement of study (if on medication).
- Able to walk independently without an aid.
- Lives in the Sydney metropolitan area.

There are no additional inclusion criteria for the subset of participants (n=2) who will undertake the Total Body PET/CT scans.

Exclusion Criteria

- Medical conditions which would preclude or interfere with study safety and interpretation (e.g., uncontrolled cardiopulmonary, metabolic, musculoskeletal, orthopaedic, and/or psychiatric diseases; undergoing active treatment for cancer; coronary artery disease, myocardial infarction and/or surgery; Type I diabetes; recent stroke or transient ischaemic attack; neurological conditions other than idiopathic Parkinson's disease).
- On beta-blocker medications.
- Cognitive impairment (Telephone Interview for Cognitive Status – Modified less than 21).
- Currently reported performing 30 min or more of high intensity aerobic exercise per week.
- Receiving deep brain stimulation.

Additional exclusion criteria for a subset of participants (n=2) who will undertake the Total Body PET/CT scans:
- Women lactating, pregnant, or of childbearing age who are aiming to fall pregnant during the study
- History of glaucoma, retinal, and/or macular disease.
- Received anti-Vascular Endothelial Growth Factor monoclonal antibody therapy the 3 months prior to recruitment.
- On carbonic anhydrase inhibitors.
- Claustrophobia
- Morbid obesity with body weight over 227kg

Study & Design

• Study Type: Interventional
• Study Design: Not specified